Literature DB >> 23315031

Different levels of various glucocorticoid-regulated genes in corticotroph adenomas.

Johan Arild Evang1, Jens Bollerslev, Olivera Casar-Borota, Tove Lekva, Jon Ramm-Pettersen, Jens Petter Berg.   

Abstract

Recently, correlations between corticotroph tumor dedifferentiation and both E-cadherin immunostaining and reduced mRNA expression of the E-cadherin gene (CDH1) have been demonstrated. The purpose of this study was to explore whether tumor dedifferentiation correlated with glucocorticoid resistance and whether the resistance was associated with both positively and negatively regulated genes. Tumor material from 20 patients with verified Cushing's disease or Nelson's syndrome operated on at Rikshospitalet, Oslo. Reverse transcription polymerase chain reaction analysis of genes such as E-cadherin (CDH1), proopiomelanocortin (POMC), glucocorticoid-induced leucine zipper (GILZ), and thioredoxin-interacting protein (TXNIP) was performed. The correlations between the expression of the GILZ, TXNIP, and POMC genes in different stages of corticotroph adenomas, the E-cadherin mRNA expression and staining pattern, and the preoperative 24-h cortisol excretion were examined. The GILZ and TXNIP expression levels were positively correlated to the CDH1 expression and were highest in microadenomas and in tumors with a high membranous E-cadherin reactivity. In contrast, the POMC expression was not significantly different between the groups. This divergence between the genes that were positively and negatively regulated by glucocorticoids could not be supported by other gene expression analyses. No correlations to urinary cortisol were found. The expression of the glucocorticoid-responsive genes POMC, GILZ, and TXNIP in corticotroph adenomas showed a remarkable variation. The pattern and variability of glucocorticoid resistance in corticotroph adenomas seem to correlate with a loss of the epithelial phenotype associated with corticotroph tumor dedifferentiation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315031     DOI: 10.1007/s12020-012-9871-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  38 in total

1.  Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity.

Authors:  Wesley B Denny; Viravan Prapapanich; David F Smith; Jonathan G Scammell
Journal:  Endocrinology       Date:  2005-03-31       Impact factor: 4.736

2.  The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis.

Authors:  Tove Lekva; Jens Bollerslev; Cybéle Kristo; Ole Kristoffer Olstad; Thor Ueland; Rune Jemtland
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

3.  Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis.

Authors:  Z Wang; Y P Rong; M H Malone; M C Davis; F Zhong; C W Distelhorst
Journal:  Oncogene       Date:  2006-03-23       Impact factor: 9.867

4.  Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.

Authors:  Gérald Raverot; Anne Wierinckx; Emmanuel Jouanneau; Carole Auger; Françoise Borson-Chazot; Joël Lachuer; Michel Pugeat; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2010-04-12       Impact factor: 6.664

5.  A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death.

Authors:  F D'Adamio; O Zollo; R Moraca; E Ayroldi; S Bruscoli; A Bartoli; L Cannarile; G Migliorati; C Riccardi
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

Review 6.  Biomarkers of pituitary neoplasms: a review (Part II).

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

7.  Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus.

Authors:  N A Huizenga; P de Lange; J W Koper; R N Clayton; W E Farrell; A J van der Lely; A O Brinkmann; F H de Jong; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

Review 8.  Ki-67 in pituitary neoplasms: a review--part I.

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

9.  Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours.

Authors:  S R R Antonini; A C Latronico; L L K Elias; A Cukiert; H R Machado; B Liberman; B B Mendonca; A C Moreira; M Castro
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

10.  Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; J A Wass; A L Harris
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  1 in total

1.  Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas.

Authors:  Maria Francesca Cassarino; Antonella Sesta; Luca Pagliardini; Marco Losa; Giovanni Lasio; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocrine       Date:  2016-05-24       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.